^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lomustine

    i
    Other names: CCNU
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    21h
    Treatment strategies and innovation for recurrent high-grade glioma. (PubMed, J Neurooncol)
    Despite poor overall outcomes, incremental progress across targeted, immune, and delivery-based approaches supports a patient centered strategy emphasizing clinical-trial enrollment, molecular profiling and symptom focused care.
    Review • Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • IDH mutation + BRAF V600E
    |
    Avastin (bevacizumab) • temozolomide • lomustine
    22d
    IPAX BrIGHT: Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P3, N=50, Recruiting, Telix Pharmaceuticals (Innovations) Pty Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lomustine
    1m
    SONOBIRD: Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM (clinicaltrials.gov)
    P3, N=560, Active, not recruiting, CarThera | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    BRAF mutation • IDH1 R132
    |
    carboplatin • temozolomide • lomustine
    2ms
    PersoMed-I: Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (clinicaltrials.gov)
    P2, N=20, Terminated, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Dec 2025 --> Sep 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jun 2025; Poor accrual
    Trial completion date • Trial termination • Trial primary completion date
    |
    TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    TP53 wild-type
    |
    cisplatin • vincristine • lomustine • Odomzo (sonidegib)
    2ms
    Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=20, Recruiting, University of California, Davis | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lomustine
    3ms
    Selection of tumor invasion-related genes to build a prognostic model and predict immune response and potential drugs for esophageal cancer patients based on WGCNA. (PubMed, Discov Oncol)
    The 10-gene prognostic model can independently predict patients' prognosis. The great correlation between ZC3H12B and multiple feature genes and immune cells may be tightly linked to EC progression.
    Journal
    |
    MAD1L1 (Mitotic Arrest Deficient 1 Like 1) • TWIST1 (Twist Family BHLH Transcription Factor 1) • TRIM28 (Tripartite Motif Containing 28)
    |
    lomustine • dexrazoxane
    4ms
    A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma ( IPAX-3 ) - Part 1 (ACTRN12625000934448)
    P3, N=18, Not yet recruiting, Telix Pharmaceuticals
    New P3 trial
    |
    IDH wild-type
    |
    lomustine
    4ms
    Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of California, Davis
    New P1 trial
    |
    lomustine
    4ms
    Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=25, Recruiting, The University of Texas Health Science Center at San Antonio | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial primary completion date
    |
    lomustine • imipramine
    4ms
    A Randomized, Open, Controlled, Multi-Centre, Phase II Clinical Study to Evaluate the Efficacy and Safety of ACT001 Monotherapy and the Combination of ACT001 with Temozolomide VS Temozolomide or Lomustine Alone in Patients with Recurrent Glioblastoma (ChiCTR2000035315)
    P2, N=75, Completed, General Hospital of Tianjin Medical University; Tianjin Shangde YaoYuan Technology Co., Ltd | Not yet recruiting --> Completed
    Trial completion
    |
    temozolomide • lomustine • dimethylamino micheliolide (ACT001)
    4ms
    Fast Evolving Glioblastoma in a Pregnant Woman: Diagnostic and Therapeutic Challenges. (PubMed, Diagnostics (Basel))
    After surgery, the patient showed resistance to Stupp protocol therapy, which was substituted with lomustine and bevacizumab combination therapy. This case illustrates that glioma may progress rapidly during pregnancy, but a favorable obstetric outcome is achievable. Management of similar cases should respect both the need for timely treatment and the patient's informed decision.
    Journal
    |
    ER (Estrogen receptor) • GPER1 (G Protein-Coupled Estrogen Receptor 1) • GFAP (Glial Fibrillary Acidic Protein)
    |
    IDH wild-type
    |
    Avastin (bevacizumab) • lomustine
    4ms
    IPAX BrIGHT: Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P3, N=50, Not yet recruiting, Telix Pharmaceuticals (Innovations) Pty Limited
    New P3 trial
    |
    lomustine